



GLAND PHARMA LIMITED

September 19, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Appointment of Chief Executive Officer (*President*) for Phixen S.A.S. (Cenexi); the wholly-owned step-down subsidiary of Gland Pharma Limited

We would like to inform you that Phixen S.A.S (which carries on the business under the name 'Cenexi'), a wholly owned step-down subsidiary of Gland Pharma Limited, has appointed a new Chief Executive Officer (*President*), for a duration of one (1) year, effective 19th September 2023.

Jim McPherson (Coaching and Consulting) Limited ("JMCL"), a legal person, has been appointed as the new Chief Executive Officer (*President*) of Phixen S.A.S and Mr. Jim McPherson, as JMCL's permanent representative, would be taking care of the functions as the new Chief Executive Officer (*President*) of the Company

Please note that Phixen S.A.S is not a material subsidiary of the Company as on 31st March 2023; but may be qualified as a Material Subsidiary as on 31st March 2024, and this disclosure is made voluntarily, as a practice of better corporate governance.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

**Yours truly,
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer**

Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of JMCL and Mr. Jim McPherson

Sl. No	Particulars	Remarks
1	Reason for change & Date of Change	Jim McPherson (Coaching and Consulting) Limited (JMCCL), a legal person, has been appointed as the Chief Executive Officer (<i>President</i>) for Phixen S.A.S, replacing Mr. Christoph Durand effective 19 th September, 2023
2	Brief profile	<p>Mr. Jim McPherson will be JMCCL's permanent representative for the purpose of its functions as Chief Executive Officer (<i>President</i>) of Phixen S.A.S.</p> <p>Mr. Jim McPherson has been a pharmaceutical executive with over 30 years of leadership experience in branded and generic pharma companies. He brings expertise in strategy development and implementation, transformational change management, business development, supply chain management, and technical operations leadership. Before taking a role at Phixen S.A.S, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK.</p> <p>Mr. Jim McPherson holds a Bachelor of Science in Industrial Studies from Napier University in Edinburgh, United Kingdom, and a Master of Business Administration from Glasgow University in Glasgow, United Kingdom.</p> <p>As the group makes strategic progress in achieving the goals at Cenexi, Jim's leadership will bring clarity, focus, and a solid client-centric mindset to the role.</p>
3	Disclosure of relationships between director	NA